X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SHASUN PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SHASUN PHARMA PANACEA BIOTECH/
SHASUN PHARMA
 
P/E (TTM) x -7.0 123.9 - View Chart
P/BV x 2.3 8.5 26.6% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 PANACEA BIOTECH   SHASUN PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
SHASUN PHARMA
Mar-14
PANACEA BIOTECH/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs14994 157.9%   
Low Rs8246 180.5%   
Sales per share (Unadj.) Rs84.1214.2 39.3%  
Earnings per share (Unadj.) Rs-18.35.3 -343.1%  
Cash flow per share (Unadj.) Rs-6.715.8 -42.3%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs83.753.3 156.9%  
Shares outstanding (eoy) m61.2556.62 108.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.40.3 420.6%   
Avg P/E ratio x-6.313.1 -48.2%  
P/CF ratio (eoy) x-17.24.4 -390.2%  
Price / Book Value ratio x1.41.3 105.3%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m7,0743,958 178.7%   
No. of employees `0002.8NA-   
Total wages/salary Rs m1,4492,164 67.0%   
Avg. sales/employee Rs Th1,874.1NM-  
Avg. wages/employee Rs Th527.0NM-  
Avg. net profit/employee Rs Th-407.7NM-  
INCOME DATA
Net Sales Rs m5,15412,127 42.5%  
Other income Rs m100229 43.5%   
Total revenues Rs m5,25412,356 42.5%   
Gross profit Rs m-7661,009 -75.9%  
Depreciation Rs m711594 119.8%   
Interest Rs m1,503415 362.1%   
Profit before tax Rs m-2,881230 -1,254.0%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60 1,900.0%   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17-73 -23.1%   
Profit after tax Rs m-1,121302 -371.1%  
Gross profit margin %-14.98.3 -178.7%  
Effective tax rate %-0.6-31.7 1.8%   
Net profit margin %-21.82.5 -873.3%  
BALANCE SHEET DATA
Current assets Rs m3,8106,884 55.3%   
Current liabilities Rs m8,3658,456 98.9%   
Net working cap to sales %-88.4-13.0 682.0%  
Current ratio x0.50.8 55.9%  
Inventory Days Days15662 252.6%  
Debtors Days Days67108 62.5%  
Net fixed assets Rs m14,4804,970 291.3%   
Share capital Rs m61113 54.1%   
"Free" reserves Rs m9032,875 31.4%   
Net worth Rs m5,1273,020 169.8%   
Long term debt Rs m5,8321,817 320.9%   
Total assets Rs m19,43313,347 145.6%  
Interest coverage x-0.91.6 -59.0%   
Debt to equity ratio x1.10.6 189.0%  
Sales to assets ratio x0.30.9 29.2%   
Return on assets %2.05.4 36.6%  
Return on equity %-21.910.0 -218.6%  
Return on capital %3.613.3 27.3%  
Exports to sales %24.546.4 52.9%   
Imports to sales %10.214.2 71.5%   
Exports (fob) Rs m1,2645,622 22.5%   
Imports (cif) Rs m5251,728 30.4%   
Fx inflow Rs m1,5395,843 26.3%   
Fx outflow Rs m9422,173 43.3%   
Net fx Rs m5973,669 16.3%   
CASH FLOW
From Operations Rs m599398 150.7%  
From Investments Rs m-438-1,635 26.8%  
From Financial Activity Rs m-3031,309 -23.1%  
Net Cashflow Rs m-14171 -198.5%  

Share Holding

Indian Promoters % 74.5 39.2 190.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 3.6 16.7%  
FIIs % 1.3 17.6 7.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 39.6 59.6%  
Shareholders   10,259 20,750 49.4%  
Pledged promoter(s) holding % 35.1 12.3 285.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Flat; Energy and Automobile Stocks Lag(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.3% while the Hang Seng is up 0.1%.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Mar 20, 2019 10:13 AM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS